We are live on ! Find out more
NKTR icon

Nektar Therapeutics

183 hedge funds and large institutions have $733M invested in Nektar Therapeutics in 2025 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 50 increasing their positions, 43 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 32

76% more capital inflows, than outflows

Capital inflows: $377M | Capital outflows: $214M

36% more call options, than puts

Call options by funds: $36.6M | Put options by funds: $26.8M

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

16% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 43

16% more funds holding

Funds holding: 158 → 183 (+25)

9.11% more ownership

Funds ownership: 76.1% → 85.21% (+9.1%)

Holders
183
Holders Change
+25
Holders Change %
+15.82%
% of All Funds
2.2%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.06%
New
61
Increased
50
Reduced
43
Closed
32
Calls
$36.6​M
Puts
$26.8​M
Net Calls
+$9.8​M
Net Calls Change
+$37.7​M

NKTR Hedge Fund Activity: Q4 2025 in Review

183 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2025, worth a combined $733M — down 11% from $824M a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new NKTR positions and 32 closed out — a net gain of 29 holders — while 50 added to existing stakes and 43 trimmed.

The largest buyer was Two Seas Capital, opening a new position worth an estimated $41.7M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $45M sold.

  • 183 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2025, up from 158 in Q3 2025.
  • Funds reported $733M of Nektar Therapeutics stock for Q4 2025, down 11% quarter-over-quarter.
  • 61 funds opened new Nektar Therapeutics positions in Q4 2025 and 32 closed out, a net change of +29 holders.
  • The largest Nektar Therapeutics buyer in Q4 2025 was Two Seas Capital, an estimated $41.7M added.
  • The largest Nektar Therapeutics seller in Q4 2025 was Farallon Capital Management, an estimated $45M sold.

Based on aggregated 13F filings for Q4 2025.